These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

934 related items for PubMed ID: 18640475

  • 1. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.
    Akazawa M, Biddle AK, Stearns SC.
    Clin Ther; 2008; 30 Spec No():1003-16. PubMed ID: 18640475
    [Abstract] [Full Text] [Related]

  • 2. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 3. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM, White CM, Coleman CI.
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [Abstract] [Full Text] [Related]

  • 4. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA.
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [Abstract] [Full Text] [Related]

  • 5. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM.
    Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
    [Abstract] [Full Text] [Related]

  • 6. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
    Suh DC, Lau H, La HO, Choi IS, Geba GP.
    Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
    [Abstract] [Full Text] [Related]

  • 7. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Friedman HS, Yawn BP.
    Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
    [Abstract] [Full Text] [Related]

  • 8. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
    Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM.
    Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
    [Abstract] [Full Text] [Related]

  • 9. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
    Mapel DW, Nelson LS, Lydick E, Soriano J, Yood MU, Davis KJ.
    COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
    [Abstract] [Full Text] [Related]

  • 10. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
    Delea TE, Hagiwara M, Stanford RH, Stempel DA.
    Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
    [Abstract] [Full Text] [Related]

  • 11. Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.
    Cyr MC, Beauchesne MF, Lemière C, Aaron SD, Blais L.
    Ann Pharmacother; 2010 Apr; 44(4):613-22. PubMed ID: 20233915
    [Abstract] [Full Text] [Related]

  • 12. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
    Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS.
    Arch Intern Med; 2009 Aug 10; 169(15):1403-10. PubMed ID: 19667304
    [Abstract] [Full Text] [Related]

  • 13. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
    Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S.
    J Med Econ; 2011 Aug 10; 14(6):769-76. PubMed ID: 21942463
    [Abstract] [Full Text] [Related]

  • 14. Economic impact of using inhaled corticosteroids without prior exacerbation among elderly patients with chronic obstructive pulmonary disorder.
    Chen S, Plauschinat CA, Wu N, Fraser K, Boulanger L.
    J Med Econ; 2011 Aug 10; 14(4):458-62. PubMed ID: 21651427
    [Abstract] [Full Text] [Related]

  • 15. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
    Dalal AA, Shah M, D'Souza AO, Crater GD.
    Respir Med; 2012 Jun 10; 106(6):829-37. PubMed ID: 22425138
    [Abstract] [Full Text] [Related]

  • 16. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
    Dalal AA, Candrilli SD, Davis KL.
    Manag Care; 2011 Aug 10; 20(8):46-50, 53-5. PubMed ID: 21887993
    [Abstract] [Full Text] [Related]

  • 17. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.
    Lee TA, Schumock GT, Bartle B, Pickard AS.
    Pharmacotherapy; 2009 Sep 10; 29(9):1039-53. PubMed ID: 19698009
    [Abstract] [Full Text] [Related]

  • 18. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.
    Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM.
    Respir Med; 2007 Jul 10; 101(7):1398-405. PubMed ID: 17368011
    [Abstract] [Full Text] [Related]

  • 19. Economic burden prior to COPD diagnosis: a matched case-control study in the United States.
    Akazawa M, Halpern R, Riedel AA, Stanford RH, Dalal A, Blanchette CM.
    Respir Med; 2008 Dec 10; 102(12):1744-52. PubMed ID: 18760581
    [Abstract] [Full Text] [Related]

  • 20. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization.
    Gagnon YM, Levy AR, Spencer MD, Hurley JS, Frost FJ, Mapel DW, Briggs AH.
    Respir Med; 2005 Dec 10; 99(12):1534-45. PubMed ID: 16291076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.